Table 1.
Summary of information of the final selected articles for the systematic review
| References | Compared to non-targeted | Types of study | Drug-NP platform | Receptor | Region | Author , year |
|---|---|---|---|---|---|---|
| [19] |
Higher cellular uptake in CD44 overexpressing (SCC7) compared to CD44 negative (NIH3T3); no difference in cellular uptake compared to free drug 30% higher tumor growth inhibition rate compared to free drug |
In vitro: murine squamous cell carcinoma cell lines (SCC7) and mouse embryo fibroblast cell lines (NIH3T3) In vivo: cell lines SCC7 xenograft |
Doxorubicin- HACE-PEG | CD44 receptor | Korea | Hyun-Jong Cho et al.,2011 |
| [31] | Higher tumor growth inhibition rate; higher survival time | In vivo: Ehrlich ascites tumor-bearing mice | Doxorubicin-PBLG | CD44 receptor | France | Kamal Kumar Upadhyay et al.,2012 |
| [29] | Higher tumor accumulation; higher tumor growth inhibition rate | In vivo: murine melanoma cell lines (B16F10) xenograft | Methotrexate-lipid-based NP | CD44 receptor | USA | Shoshy Mizrahy et al.,2014 |
| [26] | Higher cellular uptake in time-dependent manner; higher cytotoxicity – 1.75-fold for MiaPaCa-2 and twofold for AsPC-1 | In vitro: human pancreatic cancer cell lines (MiaPaCa-2, AsPC-1) | 3,4-difluorobenzylidene curcumin-styrene maleic acid | CD44 receptor | USA | Kesharwani et al., 2015 |
| [12] |
Higher cellular uptake; threefold higher cytotoxicity compared to free drug Higher tumor growth inhibition rate; 3.6-fold and 1.7-fold higher drug accumulation in tumor compared to kidney and liver |
In vitro: human colorectal cancer cell lines (HCT-116) In vivo: cell lines HCT-116 xenograft |
Topotecan hydrochloride-dendrimer | CD44 receptor | China | Xiaole Qi et al.,2015 |
| [20] |
Higher cellular uptake compared to free drug; no difference in cytotoxicity Lower relative tumor volume; higher median survival time |
In vitro: doxorubicin-resistant human breast adenocarcinoma cell lines (MCF-7/ADR) In vivo: cell lines MCF-7/ADR xenograft |
Doxorubicin- hyaluronic acid-Lys-LA10 | CD44 receptor | China | Yinan Zhong et al.,2015 |
| [21] |
4.1-Fold higher cellular uptake 2.80-Fold higher tumor accumulation; 31.89% higher tumor growth inhibition rate; higher median survival time |
In vitro: human breast adenocarcinoma cell lines (MCF-7) In vivo: murine hepatic carcinoma cell lines (Heps) xenograft |
Paclitaxel-micelle | CD44 receptor | China | Shaoping Yin et al.,2015 |
| [22] |
Higher cellular uptake; 46.3% higher cytotoxicity compared to free drug Higher in tumor targeting; lower tumor volume |
In vitro: human hepatocellular carcinoma cell lines (HepG2) In vivo: cell lines HepG2 xenograft |
Doxorubicin- hydroxyl apatite | CD44 receptor | China | Hui Xiong et al.,2016 |
| [23] |
10-Fold higher in cellular DOX level; higher cytotoxicity No difference in tumor growth inhibition rate; higher survival time |
In vitro: human breast adenocarcinoma cell lines (MCF-7) In vivo: cell lines MCF-7 xenograft |
Doxorubicin-PBLG-LA | CD44 receptor | China | Bingfeng Sun et al.,2016 |
| [27] | Higher cellular uptake; eightfold higher cytotoxicity | In vitro: human lung cancer cell lines (A549) | Cisplatin-chitosan | CD44 receptor | USA | Min Sung Suh et al.,2017 |
| [25] | Higher cytotoxicity, 1.35-fold for MDA-MB-231, and 1.1-fold lower cytotoxicity to MCF-7 | In vitro: human breast adenocarcinoma cell lines (MCF-7 and MDA-MB-231) | Rapamycin-LbL-LCNP | CD44 receptor | Egypt | May S Freag et al.,2016 |
| [24] |
higher tumor growth inhibition rate lower accumulation in the tumor |
In vitro: human liver sinusoid endothelial cells In vivo: cells 4T1-bearing mice |
PEGylated hyaluronic acid | CD44 receptor | USA | Chao Teng et al.,2019 |
| [30] | higher cytotoxicity | Invivo:4T1 tumor-bearing mice | doxorubicin dehydrochloride | CD44 receptor | China | Jianping Li et al.,2020 |
| [28] | higher accumulate in cancer cells, lower cytotoxicity |
In vitro: cells 4T1-bearing mice In vivo: cells 4T1-bearing mice |
Doxorubicin hyaluronic acid | CD44 receptor | China | Beibei Lu et al.,2020 |
Abbreviations: LbL-LCNP, layer-by-layer-liquid crystalline nanoparticle; PBLG, poly(γ-benzyl L-glutamate); PBLG-LA, G-poly(c-benzyl-L-glutamate)-lipoic acid; Lys-LA10, L-lysine methyl ester-lipoic acid;HPAEG, hyper branched poly(2-((2-(acryloyloxy)ethyl)disulfanyl)ethyl 4-cyano-4-(((propylthio)-carbonothioyl)-thio)-pentanoate-co-polyethylene glycol methacrylate; PEG, polyethylene glycol; PBLG, poly(γ-benzyl L-glutamate).